Breaking News Instant updates and real-time market news.

MRK

Merck

$63.89

0.89 (1.41%)

, INCY

Incyte

$128.80

8.31 (6.90%)

08:50
05/19/17
05/19
08:50
05/19/17
08:50

Merck leadership in NSCLC 'solidified,' says BMO Capital

BMO Capital analyst Alex Arfaei says that "the ASCO abstracts solidify Merck's (MRK) significant leadership in the important 1L-NSCLC market." The analyst says that Incyte's (INCY) Epacadostat appears to be "adding meaningful clinical benefit to Keytruda." He believes that the data "clearly indicates" that Keytruda monotherapy should be the standard of care in about 25% of 1L-NSCLC patients.

MRK

Merck

$63.89

0.89 (1.41%)

INCY

Incyte

$128.80

8.31 (6.90%)

  • 22

    May

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

MRK Merck
$63.89

0.89 (1.41%)

05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
INCY Incyte
$128.80

8.31 (6.90%)

05/18/17
BMOC
05/18/17
NO CHANGE
BMOC
Incyte price target raised to $155 from $146 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised his price target on Incyte as he increased the chances of success of the company's epacadostat + PD-1 combination in four solid tumors following favorable data. The analyst adds that the combination's position was also helped by "lackluster" data on NewLink's (NLNK) IDO, drug, GDC-0919. He raised his price target on Incyte to $155 from $146.
05/18/17
JPMS
05/18/17
NO CHANGE
Target $149
JPMS
Overweight
Incyte data to 'restore positive sentiment,' says JPMorgan
JPMorgan analyst Cory Kasimov believes last night's abstracts for epacadostat demonstrate "consistent and compelling evidence" of efficacy across multiple tumor types, consistent with what Incyte has been telling with Street. The analyst is "encouraged" by emerging data and expect it will "restore positive sentiment" in the name and add to the company's perceived strategic value. He reiterates an Overweight rating on Incyte shares with a $149 price target.
05/11/17
OPCO
05/11/17
INITIATION
Target $125
OPCO
Perform
Incyte initiated with a Perform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Incyte with a Perform and a $125 price target to reflect the valuation premium driven by takeover speculation. The analyst has no insight into the speculation but also said expectations are high going into ASCO for Incyte's epacadostat to deliver impressive benefits in combo with Keytrude in lung cancer.
05/09/17
FBCO
05/09/17
NO CHANGE
Target $152
FBCO
Outperform
Incyte price target lowered to $152 from $167 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Incyte to $152 from $167 due to moving from M&A base case valuation. While the analyst says it is possible that one day Incyte is bought, she thinks the company is progressing well in diversifying its pipeline base and de-risking its IDO inhibitor epacadostat. Young reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$659.49

-14.16 (-2.10%)

, MOMO

Momo

$42.83

-0.75 (-1.72%)

20:25
05/22/17
05/22
20:25
05/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$659.49

-14.16 (-2.10%)

MOMO

Momo

$42.83

-0.75 (-1.72%)

TTWO

Take-Two

$69.04

1.46 (2.16%)

TOL

Toll Brothers

$38.03

0.19 (0.50%)

CBRL

Cracker Barrel

$161.41

2.41 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 29

    Jun

TWX

Time Warner

$97.90

0.27 (0.28%)

, DIS

Disney

$107.63

0.11 (0.10%)

20:07
05/22/17
05/22
20:07
05/22/17
20:07
Periodicals
Zack Snyder steps away from 'Justice League,' Hollywood Reporter says »

Zack Snyder, director of…

TWX

Time Warner

$97.90

0.27 (0.28%)

DIS

Disney

$107.63

0.11 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

OMN

Omnova Solutions

$8.90

0.15 (1.71%)

19:54
05/22/17
05/22
19:54
05/22/17
19:54
Conference/Events
Omnova Solutions management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

19:52
05/22/17
05/22
19:52
05/22/17
19:52
General news
Breaking General news story  »

U.K. police says…

UHAL

Amerco

$384.37

5.63 (1.49%)

19:40
05/22/17
05/22
19:40
05/22/17
19:40
Hot Stocks
U-Haul acquires portable storage containers of Door To Door »

Amerco's U-Haul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

AAPL

Apple

$153.99

0.93 (0.61%)

19:34
05/22/17
05/22
19:34
05/22/17
19:34
Periodicals
Apple launches new Android 'switching' site, ads, AppleInsider says »

Apple has launched an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

AMZN

Amazon.com

$970.67

10.83 (1.13%)

19:34
05/22/17
05/22
19:34
05/22/17
19:34
Periodicals
Amazon plans to offer live TV channels in Europe, FT reports »

Amazon plans to offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TWTR

Twitter

$18.43

0.08 (0.44%)

19:30
05/22/17
05/22
19:30
05/22/17
19:30
Hot Stocks
Twitter hires Todd Swidler as global head of live business »

Twitter COO and CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.87

0.025 (0.10%)

19:29
05/22/17
05/22
19:29
05/22/17
19:29
Conference/Events
Takeda Pharmaceutical Co. Ltd. management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

GE

General Electric

$28.18

0.13 (0.46%)

19:27
05/22/17
05/22
19:27
05/22/17
19:27
Periodicals
EU examines potential misleading information in GE merger review, Bloomberg says »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

  • 22

    Jun

  • 02

    Oct

GOOG

Alphabet

$941.86

7.85 (0.84%)

, GOOGL

Alphabet Class A

$964.07

9.42 (0.99%)

19:20
05/22/17
05/22
19:20
05/22/17
19:20
Periodicals
Alphabet's Nest working on 4K home security camera, AndroidPolice says »

Alphabet's Nest is…

GOOG

Alphabet

$941.86

7.85 (0.84%)

GOOGL

Alphabet Class A

$964.07

9.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 24

    May

CRM

Salesforce

$88.94

1.54 (1.76%)

19:19
05/22/17
05/22
19:19
05/22/17
19:19
Conference/Events
Salesforce management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 25

    May

  • 08

    Jun

19:15
05/22/17
05/22
19:15
05/22/17
19:15
General news
Breaking General news story  »

Federal Reserve Governor…

GE

General Electric

$28.18

0.13 (0.46%)

19:13
05/22/17
05/22
19:13
05/22/17
19:13
Periodicals
Aerion in talks with GE to power faster jets, Bloomberg reports »

Aerion Corporation is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

  • 22

    Jun

  • 02

    Oct

BTU

Peabody Energy

$23.29

-0.01 (-0.04%)

19:13
05/22/17
05/22
19:13
05/22/17
19:13
Conference/Events
Peabody Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 26

    May

AAPL

Apple

$153.99

0.93 (0.61%)

19:09
05/22/17
05/22
19:09
05/22/17
19:09
Periodicals
Apple Music trial implements small fee in some countries, AppleInsider says »

Apple has started…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

TTWO

Take-Two

$69.04

1.46 (2.16%)

19:09
05/22/17
05/22
19:09
05/22/17
19:09
Recommendations
Take-Two analyst commentary at Piper Jaffray »

Take-Two delay of Red…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 25

    May

BA

Boeing

$183.67

2.91 (1.61%)

, BDRBF

Bombardier

$1.57

0.0197 (1.27%)

19:06
05/22/17
05/22
19:06
05/22/17
19:06
Periodicals
Boeing fight against Bombardier driven by missteps with Airbus, Reuters says »

Boeing's (BA) recent…

BA

Boeing

$183.67

2.91 (1.61%)

BDRBF

Bombardier

$1.57

0.0197 (1.27%)

EADSY

Airbus

$20.38

-0.23 (-1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MTSC

MTS Systems

$53.80

0.45 (0.84%)

19:05
05/22/17
05/22
19:05
05/22/17
19:05
Conference/Events
MTS Systems management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 01

    Jun

HP

Helmerich & Payne

$59.88

-0.16 (-0.27%)

, HAL

Halliburton

$47.12

-0.66 (-1.38%)

19:04
05/22/17
05/22
19:04
05/22/17
19:04
Downgrade
Helmerich & Payne, Halliburton, ProPetro Holding, U.S. Silica rating change at Goldman Sachs »

Helmerich & Payne…

HP

Helmerich & Payne

$59.88

-0.16 (-0.27%)

HAL

Halliburton

$47.12

-0.66 (-1.38%)

PUMP

ProPetro Holding

$13.59

-0.14 (-1.02%)

SLCA

U.S. Silica

$38.77

-1.65 (-4.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 20

    Jun

  • 24

    Jul

INVH

Invitation Homes

$21.67

-0.11 (-0.51%)

19:00
05/22/17
05/22
19:00
05/22/17
19:00
Conference/Events
Invitation Homes management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

ATW

Atwood Oceanics

$8.73

0.03 (0.34%)

18:59
05/22/17
05/22
18:59
05/22/17
18:59
Upgrade
Atwood Oceanics rating change at Goldman Sachs »

Atwood Oceanics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$310.35

-0.48 (-0.15%)

18:56
05/22/17
05/22
18:56
05/22/17
18:56
Periodicals
Tesla confirms less than 100 configurations for Model 3, Electrek says »

Tesla confirmed today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 02

    Oct

EXPGY

Experian

$21.43

0.125 (0.59%)

18:56
05/22/17
05/22
18:56
05/22/17
18:56
Conference/Events
Experian management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

18:55
05/22/17
05/22
18:55
05/22/17
18:55
Conference/Events
Federal Reserve Governor delivers dinner keynote speech »

Federal Reserve Governor…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.